AbbVie slips after revising guidance to reflect earnings impact [Seeking Alpha]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Seeking Alpha
The North Chicago, Illinois-based pharma giant said its full-year and Q1 2024 guidance for adjusted diluted earnings will now stand at $10.97–$1.17 and $2.18–$2.22 per share, respectively, after accounting for acquired in-process R&D and milestones expenses. The forecast reflects $164M in acquired IPR&D and milestones expense for Q1 2024 on a pre-tax basis, the company said in a regulatory filing late Wednesday . That implies a $0.08 unfavorable impact on GAAP and non-GAAP diluted earnings per share for the quarter. In February, AbbVie ( ABBV ) lowered its Q1 adjusted diluted EPS guidance to $2.26–$2.30, including a $0.42 per share dilutive impact related to its Immunogen acquisition and its pending buyout deal with Cerevel Therapeutics ( CERE However, at the time, the company reaffirmed its full-year adjusted diluted EPS guidance at $11.05–$11.25 for 2024. Recommended For You Recommended For You More Trending News About ABBV Stock Related Stocks Trending Analysis
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc. (CERE) Buyout and Encourages Investors to Contact the FirmGlobeNewswire
- Addex stock tanks after lead drug flops in Phase II epilepsy trial [Yahoo! Finance]Yahoo! Finance
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseGlobeNewswire
CERE
Earnings
- 11/1/23 - Beat
CERE
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- CERE's page on the SEC website